Reprieve Cardiovascular – a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment – announced it has raised a total of $42 million in series A financing. This total funding round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures. And the funding will advance the company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
Over 6 million Americans are living with heart failure today. ADHF is the sudden or gradual onset of the signs or symptoms of heart failure such as difficulty breathing, leg or feet swelling, and fatigue – which requires unplanned office visits, emergency room visits, or hospitalizations. ADHF is specifically caused by a rapid onset of fluid volume overload. And over one million patients a year are admitted with a primary heart failure diagnosis in the U.S., and millions more around the world, with an average hospital stay of over five days. Unfortunately, many are readmitted to the hospital within 30 days for retreating fluid volume overload, and about half are back within 6 months.
Intended for personalizing decongestion management and safely, quickly, and completely removing excess fluid to improve patient outcomes and prevent hospital readmissions, the Reprieve System monitors physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement for patients with ADHF.
Over the past three years, Reprieve Cardiovascular has grown significantly. And the leadership team is composed of domain experts in product development, regulatory, clinical, and commercial strategy who bring decades of medical device and cardiovascular experience and a track record of success in developing life-changing healthcare solutions.
Leading Reprieve is Chief Executive Officer Mark Pacyna (who joined Reprieve in May 2021). Before Reprieve, Pacyna spent 16 years with Medtronic in various leadership positions. Most recently, Pacyna served as the Vice President & General Manager of Medtronic’s Peripheral Vascular Business.
KEY QUOTES:
“Today, the standard of care for heart failure patient fluid removal is diuretics. Originally approved 60 years ago, diuretics remain the primary treatment option but can be difficult to administer optimally without real-time patient information.”
“Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients. The Reprieve System provides physicians and care teams added visibility and control throughout treatment.”
- Mark Pacyna, chief executive officer of Reprieve Cardiovascular
“We’re excited to share the Reprieve story as the company emerges from stealth mode ahead of their pivotal trial. The series A funding reinforces our belief in the Reprieve team, and in the need for a new technology that can improve the lives of patients suffering from acute decompensated heart failure around the world.”
- Jan Garfinkle, founding and managing partner of Arboretum Ventures
